Skip to main content
SpringerLink
Log in

Ocular surface changes associated with belantamab mafodotin treatment

  • Brief Communication
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Akesolo O et al (2022) Toll-like receptors: new targets for multiple myeloma treatment? Biochem Pharmacol 199:114992

    Article  CAS  PubMed  Google Scholar 

  2. Ketchum EB, Clarke A, Clemmons AB (2022) Belantamab mafodotin-blmf: a novel antibody-drug conjugate for treatment of patients with relapsed/refractory multiple myeloma. J Adv Pract Oncol 13(1):77–85

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ni B, Hou J (2022) Promising therapeutic approaches for relapsed/refractory multiple myeloma. Hematology 27(1):343–352

    Article  CAS  PubMed  Google Scholar 

  4. Chuang K, Pineda R, Liu S (2022) Belantamab mafodotin associated corneal microcyst-like epithelial changes. Am J Ophthalmol Case Rep 25:101392

    Article  PubMed  PubMed Central  Google Scholar 

  5. Marquant K et al (2021) Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report. J Hematol Oncol 14(1):159

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Andrew Kowalski, Rahul Tonk, Guillermo Amescua, and Elizabeth Vanner for their kind assistance with this study.

Funding

Beauty of Sight Foundation, NIH Center Core Grant P30EY014801 (institutional) and Research to Prevent Blindness Unrestricted Grant (institutional).

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA

    Seyyedehfatemeh Ghalibafan, Kwaku A. Osei & Alfonso L. Sabater

  2. Department of Medicine, Division of Hematology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA

    James E. Hoffman

Authors
  1. Seyyedehfatemeh Ghalibafan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kwaku A. Osei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James E. Hoffman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alfonso L. Sabater
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alfonso L. Sabater.

Ethics declarations

Ethical approval

This retrospective study was approved by the University of Miami Institutional Review Board. All procedures performed in studies involving human participants were in accordance with the ethical standards of the (place name of institution and/or national research committee) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

ALS has attended advisory board meetings for GSK plc.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ghalibafan, S., Osei, K.A., Hoffman, J.E. et al. Ocular surface changes associated with belantamab mafodotin treatment. Graefes Arch Clin Exp Ophthalmol 261, 3201–3204 (2023). https://doi.org/10.1007/s00417-023-06094-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-023-06094-1

Keywords

Search

Navigation